Expression of mitogen-activated protein kinase kinase 1 in gastric cancer and its clinical significance

ZHAO Yuan; TAO Yue-Jia; YU Guang-Fu; GUO Jia-Xin; LI Meng-Qi; XU Yuan-Yi; HUANG Yun-Ning

doi:10.16098/j.issn.0529-1356.2022.03.006

PDF(7742 KB)

Acta Anatomica Sinica ›› 2022, Vol. 53 ›› Issue (3) : 309-316. DOI: 10.16098/j.issn.0529-1356.2022.03.006

Cancer Biology

Expression of mitogen-activated protein kinase kinase 1 in gastric cancer and its clinical significance

ZHAO Yuan¹ TAO Yue-jia¹ YU Guang-fu² GUO Jia-xin¹ LI Meng-qi¹ XU Yuan-yi^1* HUANG Yun-ning^2*#br#

Author information +

History +

Abstract

Objective To investigate the expression of mitogen-activated protein kinase kinase 1 (MAP2K1) in gastric cancer and its clinical significance. Methods Immunohistochemistry and Western blotting were used to detect the protein expression of MAP2K1 in gastric cancertissues and cells. The morphology and the expression position of MAP2K1 were observed by immunofluorescence. MAP2K1 mRNA expression in gastric cancer tissues was analyzed by data mining of Starbase database and Oncomine database. The correlation between MAP2K1 mRNA expression and clinicopathological features was analyzed by UALCAN database. Survival analysis was performed using Kaplan Meier-Plotter online analysis tools. GEPIA2 database mining the relationship between MAP2K1 and gastric cancer stem cell related factors and drug resistance related factors. Results Immunohistochemistry, immunofluorescence and Western blotting showed that MAP2K1 protein was highly expressed in gastric cancer tissues and cells, and MAP2K1 was expressed in the cytoplasm of gastric cancer. According to the analysis of various databases, the expression of MAP2K1 mRNA in gastric cancer tissue was higher than that in normal gastric tissue, and the expression of MAP2K1 mRNA was closely related to gastric cancer stage, grade, lymph node metastasis and patient gender, and the overall survival rate of gastric cancer patients in the group with high MAP2K1 mRNA expression was significantly lower than that in the group with low MAP2K1 mRNA expression, which may be related to the characteristics of gastric cancer stem cells and drug resistance. Conclusion MAP2K1 is highly expressed in gastric cancer, and its expression level may affect the poor prognosis of patients by regulating stem cell related factors and drug resistance related factors. MAP2K1 may be a new diagnostic marker to determine the prognosis of gastric cancer patients.

Key words

Mitogen-activated protein kinase kinase 1 / Gastric cancer / Gastric cancer cell line AGS and HGC-27 / Western blotting / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHAO Yuan TAO Yue-jia YU Guang-fu GUO Jia-xin LI Meng-qi XU Yuan-yi HUANG Yun-ning. Expression of mitogen-activated protein kinase kinase 1 in gastric cancer and its clinical significance[J]. Acta Anatomica Sinica. 2022, 53(3): 309-316 https://doi.org/10.16098/j.issn.0529-1356.2022.03.006

References

［1］Zhou T, Chen S, Mao X. miR-145-5p affects the differentiation of gastric cancer by targeting KLF5 directly［J］. J Cell Physiol, 2019, 234(5): 7634-7644.

［2］Liu DT, Yang ZhJ, Ding B, et al. Effects of microRNA-4286 on the growth,vmigration and invasion of gastric cancer cell line HGC-27 by regulating inositol polyphosphate-4-phosphatase typeⅠ［J］. Acta Anatomica Sinica, 2021, 52(3): 405-409.(in Chinese)

刘东涛, 杨志娟, 丁波, 等. 微小RNA-4286调控肌醇多聚磷酸-4-磷酸酶Ⅰ型对胃癌细胞系HGC-27生长、迁移及侵袭的影响［J］. 解剖学报, 2021,52(3): 405-409.

［3］Huang Y, Zou Y, Lin L, et al. miR-101 regulates the cell proliferation and apoptosis in diffuse large B-cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway［J］. Oncol Rep, 2019, 41(1): 377-386.

［4］Chuang J, Wang C, Guo Y, et al. MAP2K1 mutations in advanced colorectal cancer predict poor response to anti-EGFR therapy and to vertical targeting of MAPK pathway［J］ .Clin Colorectal Cancer, 2021, 20(1): 72-78.

［5］Cedric BC, Souraka TDM, Feng YL, et al. CircRNA ZFR stimulates the proliferation of hepatocellular carcinoma through upregulating MAP2K1［J］. Eur Rev Med Pharmacol Sci, 2020, 24(19): 9924-9931.

［6］You J, Zhang Y, Li Y, et al. MiR-449a suppresses cell invasion by inhibiting MAP2K1 in non-small cell lung cancer［J］. Am J Cancer Res, 2015, 5(9): 2730-2744.

［7］Cheaney B, Bowden S, Krause K, et al. An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion［J］. Acta Neuropathol Commun, 2019, 7(1): 110.

［8］Wang X, Cheng G, Miao Y, et al. Piezo type mechanosensitive ion channel component 1 facilitates gastric cancer omentum metastasis［J］. J Cell Mol Med, 2021, 25(4): 2238-2253.

［9］Tan Z. Recent advances in the surgical treatment of advanced gastric cancer: a review［J］. Med Sci Monit, 2019, 25(25): 3537-3541.

［10］Liang X, Zhu J, Li Y, et al. Treatment strategies for metastatic gastric cancer: chemotherapy, palliative surgery or radiotherapy［J］? Future Oncol, 2020, 16(5): 91-102.

［11］Zhao Q, Cao L, Guan L, et al. Immunotherapy for gastric cancer: dilemmas and prospect［J］. Brief Funct Genomics, 2019, 18(2): 107-112.

［12］Jain AP, Patel K, Pinto S, et al. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma［J］. Sci Rep, 2019, 9(1): 18793.

［13］Schmidt J, RamisZaldivar JE, Nadeu F, et al. MAP2K1Mutations of are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation［J］. Blood, 2017, 130(3): 323-327.

［14］Chuang J, Wang C, Guo Y, et al. MAP2K1 mutations in advanced colorectal cancer predict poor response to anti-EGFR therapy and to vertical targeting of MAPK pathway［J］. Clin Colorectal Cancer, 2021, 20(1): 72-78.

［15］Cui X, Zhang A, Liu J, et al. Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression［J］. Biochem Biophys Res Commun, 2018, 504(4): 784-791.

［16］Pénzváltó Z, Lánczky A, Lénárt J, et al. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer［J］. BMC Cancer, 2014, 14(1): 837.

［17］Pérez G, López-Moncada F, Indo S, et al. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells［J］. Oncol Rep, 2021, 45(5): 58.

［18］Dai JZ, Jin HF. Research progress of stem cell markers for gastric cancer［J］. Chinese Journal of Gerontology, 2020, 40(24): 5364-5371. (in Chinese)

代俊泽, 金海峰. 胃癌干细胞标志物的研究进展［J］. 中国老年学杂志, 2020, 40 (24): 5364-5371.

［19］Zhao JJ, Zhao XQ. Function of X-linked suppressor protein and its role in tumor［J］. Chinese Journal of Biochemistry and Molecular Biology, 2021, 37(3): 321-327. (in Chinese)

赵俊杰, 赵晓琴. X连锁抑制蛋白的功能及其在肿瘤中的作用［J］. 中国生物化学与分子生物学报, 2021, 37(3): 321-327.

［20］Li YB, Lin LZh, Wang Ch, et al. Effects of Yiqi Chutan Formula combined cisplatin on xenografts inhibition and expressions of Bax,Bcl-2 in platinumresistant lung cancer［J］. Chinese Journal of Traditional Chinese Medicine, 2019, 34(2): 755-758. (in Chinese)

李元滨, 林丽珠, 王超, 等. 益气除痰方联合顺铂对可以治愈的皮下移植瘤生长及Bax, Bcl-2表达的影响［J］. 中华中医药杂志, 2019,34(2): 755-758.

［21］Chen XY, Yang Y, Wang JQ, et al. Overexpression of ABCC1 confers drug resistance to betulin ［J］. Front Oncol, 2021, 11(11): 640656.

［22］Kubiliute R, Januskeviciene I, Urbanaviciute R, et al. Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line ［J］. Sci Rep, 2021, 11(1): 6556.

Funding

the Key research and development projects of Ningxia Hui Autonomous Region; the Key research and development projects of Ningxia Hui Autonomous Region;Ningxia Natural Science Foundation Project